Insider · CIK 0001875180
Emer Leahy
Files at INTS (INTENSITY THERAPEUTICS, INC.), KTTA (Pasithea Therapeutics Corp.). First filing -, latest -.
In brief
Emer Leahy files SEC Form 4 as director at INTS (INTENSITY THERAPEUTICS, INC.), and also at KTTA (Pasithea Therapeutics Corp.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Emer Leahy has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 16, 2026 | INTS INTENSITY THERAPEUTICS, INC. | AGrant or award Stock Option (right to buy Common Stock)derivative | +5,500 | $0.00 | $0 | 5,500 | Jul 20, 2026 |
| May 1, 2026 | KTTA Pasithea Therapeutics Corp. | AGrant or award Stock Option (right to buy)derivative | +152,783 | $0.00 | $0 | 152,783 | May 5, 2026 |
| Nov 28, 2025 | KTTA Pasithea Therapeutics Corp. | AGrant or award Common Stock | +33,333 | $0.75 | $25k | 33,333 | Dec 1, 2025 |
| Oct 24, 2025 | KTTA Pasithea Therapeutics Corp. | AGrant or award Stock Option (right to buy)derivative | +42,913 | $0.00 | $0 | 42,913 | Oct 27, 2025 |
| May 2, 2025 | INTS INTENSITY THERAPEUTICS, INC. | AGrant or award Stock Option (right to buy Common Stock)derivative | +50,000 | $0.00 | $0 | 50,000 | May 6, 2025 |
Questions about Emer Leahy
Answered from the filings on this page, as of the latest one.
Is Emer Leahy buying or selling?
Emer Leahy has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Emer Leahy's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Emer Leahy has 0.
Where does Emer Leahy file Form 4?
Emer Leahy has filed Form 4 at INTS (INTENSITY THERAPEUTICS, INC.); KTTA (Pasithea Therapeutics Corp.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.